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N-6-hydroxylaminopurineHuman ITPase, encoded by the ITPA gene, and its orthologs (RdgB in Escherichia coli and HAM1 in Sac-
charomyces cerevisiae) exclude noncanonical nucleoside triphosphates (NTPs) from NTP pools. Deoxyinosine
triphosphate (dITP) and 2′-deoxy-N-6-hydroxylaminopurine triphosphate are both hydrolyzed by ITPase to
yield the corresponding deoxynucleoside monophosphate and pyrophosphate. In addition, metabolites of
thiopurine drugs such as azathioprine have been shown to be substrates for ITPase. The ITPA 94CNA [P32T]
variant is one of two polymorphisms associated with decreased ITPase activity. Furthermore, the ITPA 94CNA
[P32T] variant is associated with an increased risk of adverse drug reactions for patients treated with
azathioprine. The nature of the observed phenotypes for ITPA 94CNA [P32T] variant individuals is currently
unclear. Our biochemical assays indicate the P32T ITPase has 55% activity with dITP compared to wild-type
ITPase. Complementation experiments at 37 °C show that N-6-hydroxylaminopurine sensitivity of E. coli
rdgB mutants is reduced with a plasmid bearing the ITPA 94CNA [P32T] gene approximately 50% less than
with a plasmid bearing the wild-type ITPA gene. The reduction in sensitivity is less at 42 °C. Experiments
with synthetic lethal E. coli recA(ts) rdgB mutants show that the ITPA 94CNA [P32T] gene also complements
the recA(ts) rdgB growth deﬁciency at 42 °C approximately 40% lower than wild-type ITPA gene. Western
blot analysis indicates that the expression level of P32T ITPase is reduced in these cells relative to wild type.
Our data support the idea that P32T ITPase is a functional protein, albeit with a reduced rate of noncanonical
NTP pyrophosphohydrolase activity and reduced protein stability.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Human ITPase (encoded by the ITPA gene) is thought to exclude
noncanonical (deoxy)nucleoside triphosphates ((d)NTPs) from DNA
and RNA precursor pools [1–4]. Phosphorylation of inosine monopho-
sphate (IMP), a precursor to adenosine monophosphate (AMP) and
guanosine monophosphate (GMP), can produce deoxyinosine tri-
phosphate (dITP) [5,6]. Oxidative deamination of (deoxy)guanosine
triphosphate ((d)GTP) forms (deoxy)xanthosine triphosphate ((d)
XTP), another noncanonical (d)NTP that is a substrate for ITPase. In
addition, 2′-deoxy-N-6-hydroxylaminopurine triphosphate (dHAPTP)
is a substrate for ITPase [1]. Incorporation of these noncanonical
dNTPs into DNA can result in mutation and genetic instability [5,7].
dITP/dXTP/dHAPTP pyrophosphohydrolases, such as ITPase, prevent
this incorporation and are conserved throughout the three domains of
life [1–3,8,9].
The RdgB protein in Escherichia coli is an ortholog of ITPase [1]. It
has been shown that an E. coli recA200(ts) rdgB double-mutant strain
is inviable at 42 °C [10]. When RdgB is not available, RecA is required+1 509 359 6973.
ll rights reserved.due to the formation of double-strand breaks resulting from
endonuclease-V-initiated repair [7]. Adenylosuccinate synthase,
which is coded for by the purA gene, initiates the conversion of IMP
to AMP [6]. The temperature sensitivity of the recA200(ts) rdgB
mutants can be overcome with overexpression of the purA gene,
indicating that the role of RdgB may be to adjust the levels of
nucleotide pools [11].
N-6-hydroxylaminopurine (HAP) is a noncanonical purine that is
not known to arise spontaneously in E. coli but serves as an
excellent diagnostic tool to assess the functionality of the
noncanonical purine repair system in E. coli [7]. E. coli moa strains
are deﬁcient in molybdopterin biosynthesis. Exposure of moa
mutants to HAP results in a hypersensitive phenotype and an
elevated level of mutagenesis relative to wild-type E. coli [12]. A
moa rdgB mutant strain shows an even greater increase in HAP
sensitivity and mutagenesis, suggesting that a molybdoenzyme(s)
and RdgB protein are required for the exclusion of HAP from DNA
[7]. The HAP detoxifying molybdoenzyme activity has recently been
attributed to the ycbX and yiiM gene products [13]. Incorporation of
HAP into DNA stimulates endonuclease V to nick the DNA (M. Wan
and R.P. Cunningham, unpublished results). If this nick is crossed by
a replicative polymerase, a lethal double-strand break will occur.
Indeed, inactivation of the endonuclease V gene, nﬁ, renders moa
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increased levels of mutagenesis [7].
A common ITPAmutation in human populations is the ITPA 94CNA
[P32T] missense mutation, which changes a proline residue at
position 32 to threonine [14,15]. Biochemical studies with erythro-
cytes from individuals homozygous for the ITPA 94CNA [P32T]
mutation determined that these cells display 0% ITPase activity,
while heterozygous individuals have about 25% ITPase activity [16].
These levels are consistent with and indicate ITPase activity levels
depend on the integrity of both protomers of the ITPase dimer. The
ITPA 94CNA [P32T] allele is present in all ethnic groups, being highest
(11–19%) in Asian and lowest (1–2%) in Central and South American
populations [17,18]. ITPA deﬁciency is not linked to pathology in
afﬂicted individuals, but perturbed (d)ITP levels may be harmful
under circumstances of cellular stress.
ITPA deﬁciency may be responsible for adverse drug reactions in
patients treated with azathioprine or 6-mercaptopurine [19–21].
Metabolites of these immunosuppressive thiopurine drugs are also
substrates of ITPase [22]. These drugs have been used in the
treatment of acute lymphocytic leukemias in adults [23], childhood
acute myeloid leukemias [24], childhood non-Hodgkin's lymphoma
[25], Crohn's disease [26], ulcerative colitis [27,28], systemic lupus
erythematosus [29], and solid organ transplantations [30]. A study
of inﬂammatory bowel disease patients treated with azathioprine
revealed that side effects such as rash, ﬂu-like symptoms, and
pancreatitis were correlated with the P32T mutation [19]. Other
studies have linked side effects with azathioprine such as
myelosuppression and hepatotoxicity to the ITPA 94CNA [P32T]
mutation [31].
Currently two hypotheses exist that help to explain the
decreased activity associated with the ITPA 94CNA [P32T] mutation.
Stenmark et al. suggest that the mutation causes a shift of a loop in
the protein, which renders the protein catalytically inactive by
disrupting substrate binding and/or catalysis [3]. Conversely Arenas
et al. propose that the ITPA 94CNA [P32T] mutation causes
missplicing at the mRNA level. They propose that missplicing is
due to destruction of an exonic splicing silencing element in exon 2,
and activation of two cryptic 5′ splice sites, which results in the
missplicing of exons 2 and 3 [14]. Our research aims to investigate
the validity of these two models for explaining the observed
deﬁciency in individuals with the ITPA 94CNA [P32T] mutation by
measuring pyrophosphohydrolase activity in vitro and in vivo.
2. Materials and methods
2.1. E. coli strain construction and growth conditions
The growthmediumwas LB (10 g bacto-tryptone, 5 g yeast extract,
10 g NaCl per liter dH20 at pH 7.2). The following concentrations of
antibiotics were used: kanamycin, 34 μg/ml; chloramphenicol, 34 μg/
ml; tetracycline, 20 μg/ml; ampicillin, 50 μg/ml [32]. Cell growth was
monitored using a Shimadzu UV-1700 PharmaSpec spectrophotom-
eter at 600 nm. E. coli strains were constructed using P1-mediated
transductions [33]. All parental strains were obtained from the Coli
Genetic Stock Center unless noted. The moa rdgB strain, designated
EWU2, was made by ﬁrst transducing the moa-250::Tn10d(Tc) allele
[7] into KL16 cells and selecting for tetracycline resistance. This strain
was then transduced with the rdgB3::kan allele [10] followed by
selection for kanamycin resistance. Construction of EWU2 was
veriﬁed by determining HAP sensitivity using a HAP gradient plate
assay [7]. The recA200(ts) rdgB strain, designated EWU5, was
constructed at 30 °C by ﬁrst cotransducing the recA200(ts) allele
linked to slrD300::Tn10 into KL16 and selecting for transductants that
were tetracycline-resistant and UV-sensitive at 42 °C [34]. A second
transduction followedwith the rdgB3::kan allele [10] and selection for
kanamycin resistance.2.2. Plasmid construction
Construction of plasmids pET28a-ITPA, pBJH-ITPA, and pBJH-EV
(empty vector) was described previously [1]. Construction of pET28a-
P32T ITPA was performed using the mega-primer method for site-
directed mutagenesis, which employs a two-step PCR protocol using
pET28a-ITPA as starting material [35]. Incorporation of a single CNA
base change at position 94 was conﬁrmed by DNA sequencing.
Plasmid pBJH-P32T ITPA was constructed by NdeI–EcoRI double
digestion of pET28a-P32T ITPA and pBJH-EV followed by ligation of
the P32T ITPA fragment into pBJH. Construction of the pBJH plasmids
in this manner allows for constitutive protein expression to be driven
by the native E. coli promoter for endonuclease IV.
2.3. Overexpression and puriﬁcation of His6-tagged P32T ITPase
Overexpression and puriﬁcation of P32T ITPase were performed as
described previously for wild-type ITPase [1].
2.4. Analysis of deoxyribonucleoside triphosphate pyrophosphohydrolase
activity of P32T ITPase
Enzyme kinetics assays and data analysis for P32T ITPase was
performed as described previously for wild-type ITPase [1].
2.5. HAP cytotoxicity complementation assay
HAP cytotoxicity was determined for E. coli moa rdgB double
mutants (EWU2) transformed with pBJH-EV, pBJH-ITPA, or pBJH-P32T
ITPA as described previously [1].
2.6. Synthetic lethality complementation assay
Fresh 30 °C overnight cultures of E. coli recA200(ts) rdgB double
mutants (EWU5) transformed with pBJH-EV, pBJH-ITPA, or pBJH-P32T
ITPA were diluted into 25 ml of fresh LB-ampicillin broth (250×
dilution ratio) pre-warmed at 42 °C. Cultures were incubated in a
42 °C shakingwater bath. Cell growthwasmonitored over a 10-h time
course by determining optical density at 600 nm.
2.7. Western blotting
EWU5 cells were transformed with pBJH-EV, pBJH-ITPA, and pBJH-
P32T ITPA expression plasmids and grown at 30 and 42 °C in fresh LB-
ampicillin broth to a density of approximately 2×108 cells/ml. The
cells were collected by centrifugation, and the bacterial pellets were
washed with Tris-buffered saline (pH 7.6) (TBS), resuspended in TBS
containing 0.1% Tween-20 (TBS-T) at a ratio of 2 ml/g of cell paste and
lysed by sonication using a Vibra-Cell sonicator (Sonics & Materials,
Inc., Newtown, CT) set at 40% amplitude. The cell lysates were
centrifuged for 20 min at 67,509 g. A Bradford Assay was performed
on the supernatants to determine protein concentrations. BSA was
used as a standard.
SDS-polyacrylamide gel electrophoresis was performed on a 12%
separating gel using a discontinuous buffer system (Bio-Rad). Samples
consisting of 5 μg of protein from each cleared lysate were diluted in
gel buffer containing 4% SDS and 20% glycerin in 0.05 M Tris (pH 6.8)
and were reduced with 2% β-mercaptoethanol prior to electrophore-
sis. For immunoblotting, electrophoretic transfer of proteins to
nitrocellulose was performed in a Trans-Blot SD Semi-Dry apparatus
(Bio-Rad) according to manufacturer's instructions. Following trans-
fer, the nitrocellulose blot was blocked overnight with 5% powdered
milk in TBS-T at 4 °C. The nitrocellulose blot was then incubated with
primary antibody, rabbit PolyAb Anti-ITPA (from Proteintech Group,
Inc.), at a dilution of 1:800 for 1 h at room temperature followed by
three 15-min washes in 5% powdered milk in TBS-T. The blot was
Fig. 1. HAP cytotoxicity complementation assay. Fresh overnight cultures of EWU2
transformed with plasmids bearing constitutively expressed wild-type ITPase (WT),
P32T ITPase (P32T), or empty vector (EV) were serially diluted and then plated on LB-
ampicillin plates containing various concentrations of HAP. Surviving colonies were
scored after 48-h incubation at (A) 37 °C or (B) 42 °C. Each result is the mean±SE of
three to ﬁve independent experiments.
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anti-rabbit), for 1 h at room temperature followed by three 15-min
washes in 5% powdered milk in TBS-T. Immunoblots were developed
using chemiluminescence (Super Signal Femto Maximum Sensitivity
Kit from Pierce Protein Research Products) according to the
manufacturer's instructions. The blot was imaged using a Fluoro HD
chemiluminescent imager from Alpha Innotech Corp. AlphaEase FC
and FluorChem 9900 programs were used for protein detection and
quantiﬁcation.
3. Results
3.1. Kinetic analysis of P32T ITPase
Table 1 shows the results of our in vitro kinetic analysis with
P32T ITPase using the presumed physiological substrate dITP.
Enzyme preparations and experimental manipulations for wild
type and P32T ITPase were performed by the same experimenter
under identical conditions. P32T ITPase obeyed Michaelis–Menten
kinetics over the same substrate concentration previously speciﬁed
for wild-type ITPase [1]. ITPase has previously been documented to
be subject to substrate inhibition [1,4]; therefore, data points not
subject to substrate inhibition were chosen to determine kinetic
constants using a standard nonlinear least squares estimation tech-
nique. From Table 1, it can be seen that the speciﬁcity constant
(kA) for the P32T enzyme is approximately 55% of the value for
wild-type enzyme. The difference in kA appears to be derived from
the rate of catalysis (kcat) rather that the Michaelis constant (Km).
In our case Km is reﬂective of substrate binding [36]. Therefore, our
data suggest that the mutant enzyme binds substrate appropria-
tely, however, kcat is reduced approximately 50% for the mutant
enzyme.
3.2. HAP cytotoxicity complementation assay
Cytotoxicity tests were performed to quantify the activity of the
P32T mutant ITPase in vivo against exogenous noncanonical purine
nucleoside triphosphates. For this assay plasmid expressing wild-
type ITPase or the mutant P32T ITPase driven by a constitutively
expressed E. coli promoter or empty vector was transformed into an
E. coli moa rdgB double mutant. Fig. 1A shows our cytotoxicity
results after 48 h of growth at 37 °C on rich media containing
various concentrations of HAP. We observed that moa rdgB cells
transformed with empty vector are extremely sensitive to HAP,
whereas transformation of these cells with plasmids bearing wild-
type ITPA or ITPA 94CNA [P32T] complements the HAP-sensitive
phenotype to varying degrees. The level of survival for the cells
transformed with wild-type plasmid is equivalent to the level
reported for E. coli moa cells at these HAP concentrations [1]. This
suggests that expression of wild-type ITPase from our plasmid fully
complements the chromosomal rdgB mutation and indicates that
ITPase activity from the plasmid is at a level equivalent to rdgB
activity from the E. coli chromosome. Conversely, the observed level
of complementation for the strain expressing P32T ITPase is
between 100% and 25% of wild-type complementation. At 5 and
10 μg/ml HAP no statistically signiﬁcant difference in survival isTable 1
Kinetic constants.
Genotype Km kcat kA
μM 1/s 1/mM-s
P32T 27.9±5.8 38.0±1.8 1361±289
Wild type[1] 32.5±2.8 79.6±2.0 2448±218
Each result is the mean±SD from three independent experiments.observed between strains expressing wild-type and P32T ITPase;
however, at 25 μg/ml HAP, we observed a roughly 50% decrease in
survival for cells expressing P32T ITPase compared to cells
expressing wild-type ITPase. At 50 μg/ml HAP the level of survival
for cells expressing P32T ITPase is roughly 25% of cells expressing
wild-type ITPase. At this concentration, the level of survival for cells
expressing P32T ITPase is equivalent to the level seen for cells
transformed with empty vector at 10 μg/ml HAP. Therefore, it
appears that the P32T ITPase has functional pyrophosphohydrolase
activity in vivo against dHAPTP at a rate somewhat reduced
compared to wild type.
To address the possibility that the P32T ITPase may have reduced
stability compared to the wild-type enzyme, the HAP cytotoxicity
assay was performed with incubation at 42 °C. Fig. 1B shows that for 5
and 10 μg/ml HAP the mean level of survival for cells expressing P32T
ITPase is about 50% lower than the level for cells expressing wild-type
ITPase. At 25 and 50 μg/ml HAP, themean level of survival for the cells
expressing P32T ITPase is about 30% of cells expressing wild-type
ITPase. Despite the level of error in the 42 °Cmeasurements, it appears
that a slight reduction in P32T ITPase activity is observed at elevated
temperatures. Therefore, our data suggest that the P32T mutant may
have reduced protein stability at elevated temperatures.
3.3. Synthetic lethality complementation assay
Complementation of synthetic lethality in recA rdgB cells was
performed to quantify P32T ITPase activity in vivo against the
presumed physiological substrate dITP. E. coli recA200(ts) rdgB double
mutants are inviable at the non-permissive temperature of 42 °C [10].
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rendering cells deﬁcient in homologous recombination [37], an
activity required for repair of the lethal double-strand breaks that
form in rdgB mutants [7]. For this assay, we transformed E. coli
recA200(ts) rdgB double mutants with the same plasmids used in the
HAP cytotoxicity complementation assay (above). Fig. 2 shows that
the recA200(ts) rdgB double mutant transformed with empty vector
does not grow at the non-permissive temperature over a 10-h time
course. In contrast, transformation of these cells with plasmids
bearing either the wild-type ITPA or the ITPA 94CNA [P32T] gene
reverses the synthetic lethal phenotype to varying degrees. Over the
ﬁrst half of the time course, cells transformed with plasmid bearing
wild-type ITPA or ITPA 94CNA [P32T] have growth curves that are
indistinguishable from one another. For the latter half of the time
course, the cells expressing P32T ITPase show a reduced rate of
growth compared to the cells expressing wild-type ITPase. Nonethe-
less, cells expressing P32T ITPase are viable and continue to grow over
the duration of the time course. At the 10-h time point, the level of cell
growth for the cells expressing P32T ITPase is 60% of the level
observed for the cells expressing wild-type ITPase, relative to the cells
containing the empty vector plasmid. Fig. 3 shows that these cells are
viable after 48-h incubation at the non-permissive temperature;
however, these cells appear to grow more slowly than those
transformed with plasmid bearing wild-type ITPA. Note for the 42 °C
plate that an approximately equal number of colonies are observed for
cells transformed with plasmid bearing wild-type ITPA or ITPA 94CNA
[P32T].
Investigation of the expression levels for wild-type and P32T
ITPase in these cells indicate that decreased levels of P32T ITPase
contribute to the slow growth phenotype for the cells transformed
with plasmid bearing ITPA 94CNA [P32T]. The representative Western
blot in Fig. 4 shows that at 30 °C, the level of expression for wild-type
ITPase is somewhat greater than the level seen for P32T ITPase.
However, at 42 °C the level of expression is noticeably reduced for the
P32T ITPase, while the level for the wild-type ITPase is equivalent to
the level seen at 30 °C. Data from a semiquantitative analysis of
duplicate Western blots are presented in Table 2. At 30 °C the level of
P32T ITPase is approximately 25% lower than the wild-type level,
while the level of P32T ITPase is roughly 50% lower than the wild-type
level at 42 °C. Additionally, it appears that growth at 42 °C results in an
expression level of P32T ITPase that is 35% lower than the expression
at 30 °C, while the wild-type level remains unchanged. Altogether, our
results suggest that the ITPA 94CNA [P32T] mutation results in a
reduction in ITPase activity and ITPase stability. Presumably both
defects contribute to an obvious slow growth phenotype for recAFig. 2. Synthetic lethality complementation assay. Fresh overnight cultures of EWU5
transformed with plasmids bearing constitutively expressed wild-type ITPase (WT),
P32T ITPase (P32T), or empty vector (EV) were diluted in pre-warmed LB-ampicillin
media and incubated in a shaking water bath at 42 °C. Optical density measurements
were taken over a 10-h time course. Each result is the mean±SE from three
independent experiments.
Fig. 3. Chronic synthetic lethality complementation assay. Fresh overnight cultures of
EWU5 transformed with plasmids bearing constitutively expressed wild-type ITPase
(WT), P32T ITPase (P32T), or empty vector (EV) were serially diluted in LB media and
5 μl of each dilution was spotted in duplicate onto LB-ampicillin plates pre-warmed at
30 or 42 °C. Plates were incubated at appropriate temperature for 48 h and
photographed under white light. (A) 30 °C plate; (B) 42 °C plate.
Fig. 4. Western blot analysis. EWU5 cells were transformed with plasmids bearing
constitutively expressed wild-type ITPase (WT), P32T ITPase (P32T), or empty vector
(EV) and grown at 30 and 42 °C. Cells were harvested, and total protein concentration
was determined. Western blotting was performed as described in Materials and
methods with 5 μg of total protein from each cleared cell lysate using rabbit PolyAb
anti-ITPA and HRP-conjugated secondary antibody. Lane 1, EV at 30 °C; lane 2, WT at
30 °C; lane 3, P32T at 30 °C; lane 4, WT at 42 °C; lane 5, P32T at 42 °C.
Table 2
Semiquantitative Western blot analysis.
Genotype 30 °C 42 °C
P32T 73±8% 47±8%
Wild type 100% 112±29%
Each result is the mean±error from two independent blots, relative to wild type at
30 °C.
1 The authors wish to note that during the revision of our manuscript, another
article has been published containing similar experimental results where the authors
have reached conclusions that are consistent with the conclusions presented herein
[42].
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monophosphate into genomic DNA and resulting double-strand
breaks [1].
4. Discussion
The experimental results presented herein suggest that the P32T
ITPase is a functional protein, which has a reduced rate of catalysis and
reduced stability compared to wild-type ITPase. Our in vitro and in
vivo measurements suggest that the P32T ITPase has about 50%
activity of the wild-type ITPase. From our kinetic assays, we have
measured a 45% reduction in catalytic efﬁciency with dITP as a
substrate for P32T ITPase compared to wild-type ITPase. Likewise,
with our synthetic lethal complementation assay, we observed a
rescue with the ITPA 94CNA [P32T] bearing plasmid that was
approximately 60% of the wild-type ITPA level. Similarly, the 37 °C
HAP cytotoxicity complementation assays demonstrated that ITPA
94CNA [P32T] bearing plasmid reversed that HAP-sensitive phenotype
to a level that was about 50% that of wild-type ITPA bearing plasmid.
For the synthetic lethal complementation assay, dITP is the presumed
lethal metabolite that ITPase is preventing from accumulating in DNA
precursor pools. Therefore, from the data presented above, we can
infer that P32T ITPase has equivalent pyrophosphohydrolase activity
with both dITP and dHAPTP in vivo. Indeed, wild-type ITPase has been
shown to have equivalent pyrophosphohydrolase activity in vitro
with dITP and dHAPTP as substrates [1].
Investigation of protein levels for wild type and P32T ITPase
suggests that the mutant form has reduced stability compared to wild
type. Interestingly, our Western blotting data indicate that the P32T
ITPase is present at a lower level than wild-type ITPase. Protein
expression from both wild-type ITPA and ITPA 94CNA [P32T] in the
cells used for Western blot analysis is driven by the constitutively
expressed native E. coli promoter for endonuclease IV. Therefore, we
interpret a reduction in protein levels at 30 °C to indicate that the
P32T ITPase is an inherently less stable protein than the wild-type
ITPase. The fact that lower levels of P32T ITPase are observed at 30 °C
than the level observed for wild type suggests that the substitution of
proline with threonine at this position leads to a protein conformation
that is more susceptible to degradation than the wild-type structure.
In addition, the stability of P32T ITPase appears to be further reduced
at 42 °C, whereas the wild-type protein levels remain constant over
this temperature range. This is consistent with our results for the HAP
cytotoxicity assay where, relative to wild-type expressing cells, we
observed a greater reduction in survival for the P32T ITPase
expressing cells at 42 °C than we did at 37 °C. Altogether we ﬁnd
that reduced catalysis and reduced protein stability contribute to a
roughly 50% reduction in ITPase activity in vivo for P32T ITPase.
Our data have inconsistencies with the hypothesis postulated by
Stenmark et al., who suggested that the P32T mutation would perturb
ITPase structure in a way that would render the protein catalytically
inactive [3]. Proline 32 is located in a loop on the outer surface of the
protein, distal from the dimer interface and substrate binding pocket.
Pro-32 is separated from an extended loop containing proposed active
site residues Asp-41 and Glu-44 by a short ﬁve-residue beta-strand
[3]. We propose a model that is consistent with our kinetic and
Western blot data in which a change from the conformationally
restrictive proline to threoninemay cause an alteration of the Asp-41/Glu-44 containing loop resulting in a reduced rate of catalysis (kcat)
and reduced protein stability. However, this extended loop does
extend into the dimer interface; therefore, our data do not rule out the
possibility that “cross-talk” between subunits of this homodimeric
protein may be perturbed. In fact, cooperativity has been reported for
the E. coli ortholog [9]. Nonetheless, because Km was unchanged for
the mutant, it seems less likely that any possible cooperativity would
be affected. In addition, this substitution may cause the Asp-41/Glu-
44 containing loop to become more susceptible to misfolding or
degradation by proteolysis.
The P32T mutation is understood to result in an absence of ITPase
activity as measured in red blood cells derived from a patient with the
ITPA 94CNA [P32T] mutation [16]. Insight into a potential mechanism
for this deﬁciency has come from the analysis of mRNA transcripts
from peripheral blood leukocytes of patients bearing the ITPA 94CNA
[P32T] allele [14,15]. These data suggest that amissplicing event in the
ITPA 94CNA [P32T] transcript can result in decreased levels of mature
ITPA 94CNA [P32T] transcripts. Assuming that missplicing of the ITPA
94CNA [P32T] transcript is not speciﬁc to peripheral blood leukocytes,
our experimental data suggest that the basis of ITPase deﬁciency in
these patients is primarily the result of a defect in mRNA splicing,
rather than the production of a grossly unproductive enzyme.We ﬁnd
that the P32T ITPase is a functional protein both in vivo and in vitro.
Therefore, if normal levels of P32T ITPase protein were produced in an
affected patient, we could expect the level of ITPase activity in
samples from that patient to be detectable. Because ITPase activity has
been reported to be undetectable in individuals with the ITPA 94CNA
[P32T] mutation, it seems much more likely missplicing is occurring
and that the level of missplicing is varied among tissues, with red
blood cells being severely affected. In addition, several reports have
indicated strong substrate inhibition for ITPase at elevated levels of
(d)ITP [1,38,39]. Further analysis of our kinetic data obtained for wild-
type ITPase under substrate inhibition conditions with dITP as a
substrate [1] indicates that the inhibitor constant (Ki) is 277 μM,
which is approximately nine times the value of the Km for this
enzyme–substrate pair. Therefore, a reduction of ITPase activity in an
individual with the ITPA 94CNA [P32T] mutation could potentially be
compounded four-fold. In essence, a missplicing event would lead to
decreased expression of an enzyme that is catalytically compromised
and less stable, which in turn would result in an elevated
concentration of ITP, which would reduce ITPase activity via substrate
inhibition. It is important to note the recent observation that Itpa
homozygous knock-out mice die before weaning and have gross
cardiac abnormalities [40]. In fact, the birth ratio indicates that over
half of the homozygous null offspring died before birth [40].
Furthermore, ITPA has been found to be expressed ubiquitously in
mice, supporting a need for functional protein in many tissues [41].
Therefore, barring some large differences among mammals, it seems
unlikely that the ITPA 94CNA [P32T] mutation leads to a true null
phenotype in humans. Instead we propose that the ITPA 94CNA [P32T]
mutation results in a missplicing event that leads to the production of
decreased levels of P32T ITPase, which functions at a rate that is about
half that of wild type, is less stable than wild type, and is subject to
substrate inhibition.1
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